Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

École Polytechnique de Montréal

$25,000.00

Safety evaluation of nanomedical devices

EF 2013-14

Résumé
Pega Medical is a company specializing in the design, development, evaluation and manufacturing of medicaldevices. It is also the first Canadian company dedicated to Bioengineering design; regulatory and; testingservices for OEMs. Pega Medical is ISO 13485 and ISO 9001 certified and a member of the ASTM committeeF04 on Medical and Surgical Materials and Devices. Regulatory clearance of new medical devices is one of thePega's strengths. Pega's strong technical background coupled with a solid understanding of US-FDA andCanadian TPP has been a key factor in submitting successful pre-market applications. To continue its growth,Pega would widen her portfolio to nano scale medical devices adapting to new paradigms of nanomedicine,specifically the evaluation of their bioperformance (biosafety, toxicity, efficacy) and their approbation. For thispurpose, Pega Medical proposed this project in order to collaborate with Pr. L'Hocine Yahia's team from EcolePolytechnique of Montreal, who are experts in the biocompatibility and bioperformance evaluation ofnano/micromedical devices.We aim to develop protocols and procedures appropriate for assessment of safety and efficacy of nanomaterialsand nanomedical devices. These tests include physicochemical characterization as well as evaluation of cellviability, hemocompatibility, genotoxicity, or immunosafety. These methods for biocompatibility-testing ofnanomedical devices could be ultimately incorporated into American Society for Testing and Materials (ASTMInternational) standards such as the three new ASTM standards, designated E2524, E2525, and E2526.Furthermore, it is essential that protocols be standardized and models validated in this transition era beforeaccepted standards exist. This study may lead to develop Standard Operating Procedures (SOPs) forphysicochemical and biocompatibility characterization of nano scale medical devices.
Programme
Engage Grants Program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
455624-2013
Name nom
Yahia, LHocine
Department département
Génie mécanique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Safety evaluation of nanomedical devices
Keyword
NSERC
Application summary
Pega Medical is a company specializing in the design, development, evaluation and manufacturing of medicaldevices. It is also the first Canadian company dedicated to Bioengineering design; regulatory and; testingservices for OEMs. Pega Medical is ISO 13485 and ISO 9001 certified and a member of the ASTM committeeF04 on Medical and Surgical Materials and Devices. Regulatory clearance of new medical devices is one of thePega's strengths. Pega's strong technical background coupled with a solid understanding of US-FDA andCanadian TPP has been a key factor in submitting successful pre-market applications. To continue its growth,Pega would widen her portfolio to nano scale medical devices adapting to new paradigms of nanomedicine,specifically the evaluation of their bioperformance (biosafety, toxicity, efficacy) and their approbation. For thispurpose, Pega Medical proposed this project in order to collaborate with Pr. L'Hocine Yahia's team from EcolePolytechnique of Montreal, who are experts in the biocompatibility and bioperformance evaluation ofnano/micromedical devices.We aim to develop protocols and procedures appropriate for assessment of safety and efficacy of nanomaterialsand nanomedical devices. These tests include physicochemical characterization as well as evaluation of cellviability, hemocompatibility, genotoxicity, or immunosafety. These methods for biocompatibility-testing ofnanomedical devices could be ultimately incorporated into American Society for Testing and Materials (ASTMInternational) standards such as the three new ASTM standards, designated E2524, E2525, and E2526.Furthermore, it is essential that protocols be standardized and models validated in this transition era beforeaccepted standards exist. This study may lead to develop Standard Operating Procedures (SOPs) forphysicochemical and biocompatibility characterization of nano scale medical devices.